Sponsors / NGNE
NGNE

Neurogene Inc.

Company identity checked against sources

Browse linked trials and recorded changes, or follow this company for updates.

Follow company
1Trials in this database
5Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

Completion dates · Pro

Which trial dates moved later?

Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features

Included trials

Check company identity source
TrialSponsorPhaseStatusPrimary completion
A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett SyndromeNCT05898620NGNEPhase 3Active not recruiting2029-12Estimated

Latest recorded trial changes

A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome

NCT05898620 · Neurogene Inc.

· 4 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: Incidence of Treatment Emergent Adverse Events (TEAEs) Measure: Incidence of Serious Adverse Events (SAEs) Measure: Incidence of Adverse Events of Special Interest (AESIs) Measure: Incidence of clinical laboratory abnormalities Measure: Incidence of new physical and neurologic exam abnormalities

+ After

Measure: Efficacy of NGN-401

Planned enrollment increased by 19 participants

− Before

14 participants (planned)

+ After

33 participants (planned)

Primary completion date changed

− Before

Oct 2029

+ After

Dec 2029

Phase changed

− Before

PHASE1, PHASE2

+ After

PHASE3

Check registry source